Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

BioSpecifics Technologies Corp. (BSTC) Provides Update On XIAFLEX Treatment And Presents Findings At Several Conferences

|Includes: BioSpecifics Technologies Corp. (BSTC)

BioSpecifics Technologies, a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, remains busy, recently announcing a series of presentations and also releasing a safety update for its product, XIAFLEX®. Marketed in the United States for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm, XIAFLEX is in clinical development for the treatment of several additional promising indications.

Tom Wegman, President of BioSpecifics, has made several presentations over the last few months. Most recently Mr. Wegman spoke at the UBS Global Life Sciences Conference on Thursday September 20th, 2012. Earlier in the month Mr. Wegman presented at two conferences: the Rodman & Renshaw 14th Annual Health Care Conference on September 10th, and the ThinkEquity 9th Annual Growth Conference on September 13th. All presentations were held in New York, NY, and replays of the presentations are available on the company's Web site.

On September 5th, 2012, Biospecifics Technologies announced a safety update following 30 months of post-approval use in the U.S. for XIAFLEX. As reported by BioSpecifics' strategic partner Auxilium Pharmaceuticals, after about 27,000 injections were administered to approximately 21,000 patients in the U.S., there was no clinically meaningful change in the nature of events expected relative to the clinical trial safety profile.

Thomas L. Wegman, President of BioSpecifics, stated, "We are very encouraged by the continued low number of adverse events reported since the U.S. launch of XIAFLEX for Dupuytren's contracture patients, which we believe reaffirms the excellent safety profile of XIAFLEX. These data also demonstrate the success of Auxilium's physician and sales force training programs and we look forward to the launch of its pilot program for select rheumatology clinics later this year."

For more information on BioSpecifics Technologies, visit

Please see disclaimer on the MissionIR website